CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that activation of SIRT1, a member of the sirtuin family of enzymes, was shown to be neuroprotective in an animal model of optic neuritis (inflammation of the optic nerve that can cause a complete or partial loss of vision). These findings appear in a poster presented at the 132nd Annual Meeting of the American Neurological Association, titled “Neuroprotection in CNS Demyelinating Disease by SIRT1 Activators: A Potential Oral Therapy.”
